AbbVie granted EU nod for Boey anti-wrinkle therapy (ABBV:NYSE)

AbbVie (ABBV) unit Allergan wins EU approval for the Boey anti-wrinkle injectable for temporary improvement of frown lines across 30 European countries. Read more here.

AbbVie granted EU nod for Boey anti-wrinkle therapy (ABBV:NYSE) | Seeking Alpha

Save

Play

(

1min

)

Comments

Michael Vi/iStock Editorial via Getty Images

AbbVie (

ABBV

) unit, Allergan Aesthetics, announced on Friday that the European Commission approved its anti-wrinkle therapy, Boey, for the temporary improvement of glabellar lines, commonly known as frown lines.

According to the company, the facial injectable will therefore be available in

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please

report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search field

Entering text into the input field will update the search result below

Entering text into the input field will update the search result below

Recommended For You

More

Trending News

See More

»